Status:
COMPLETED
Recovery Effect of Sugammadex Measured by Bispectral and Neurosense Indices
Lead Sponsor:
Hopital Foch
Conditions:
Anesthesia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
It has been demonstrated that antagonism of neuromuscular blockade (neostigmine 0.04 mg kg-1) affects depth of anaesthesia with an increase in bispectral index (mean maximal change of 7.1) and middle-...
Eligibility Criteria
Inclusion
- patients scheduled to receive general anesthesia with muscle relaxation
Exclusion
- contra-indication to the administration of propofol, remifentanil, rocuronium and to the use of the Bispectral Index or NeuroSense monitor
- known drug allergy or hypersensitivity to a drug used in the study
- history of central brain injury
- patient treated with a psychotropic agent
- patient with a pacemaker
- severe renal insufficiency
- treatment by toremifene, flucloxacillin or fusidic acid in the preoperative or immediate postoperative period
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01161004
Start Date
September 1 2010
End Date
August 1 2011
Last Update
May 24 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Foch
Suresnes, France, 92151